Pfizer Inc. says it has agreed to buy King Pharmaceuticals Inc. for $3.6 billion in cash.
The price for the Tennessee drugmaker represents a hefty 40 percent premium over King's closing price on Monday. It would broaden Pfizer's array of painkillers and drug delivery devices.